surmount-1 trial tirzepatide non-diabetic weight loss SURMOUNT-1: Drastically Reduces in Obese Patients SURMOUNT 1 // Three-Year Obesty

The SURMOUNT-1 trial showed meaningful weight loss at every dose level, with 5mg producing an average 15% body weight reduction over 72 weeks

Many users inject it in abdominal fat for convenience regardless of injury location

Increased Insulin Secretion When blood sugar levels rise, tirzepatide stimulates the pancreas to release insulin , allowing glucose to enter cells and reducing blood sugar levels

Preference for less frequent injections (weekly versus daily)

Less common serious side effects include seizures, increased blood pressure (hypertension) and heart rate, liver damage, increased pressure in the eye (glaucoma), and severe skin reactions

How Sermorelin Works in the Body Sermorelin activates the effects of the body's own GH hormone-releasing hormone